[A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].

A 54-year-old female was diagnosed with invasive ductal carcinoma (pT3N1M0, Stage IIIA, estrogen receptor positive [ER (+)], progesterone receptor positive [PgR (+)], human epidermal growth factor receptor type 2 [HER2] score 0) and was treated by preoperative chemotherapy with weekly paclitaxel followed by 5-fluorouracil(5-FU) plus epirubicin plus cyclophosphamide regimen(FEC). Partial mastectomy with axillary dissection was performed. The pathological examination disclosed that the tumor was scirrhous carcinoma, and a pathological partial response was achieved by chemotherapy. Multiple bone metastases were detected 18 months after the surgery during treatment with letrozole as adjuvant therapy. Retroperitoneal metastases with hydronephrosis and a lung metastasis were detected 28 months after the surgery, even though exemestane and zoledronate were administrated after detection of the bone metastases. Chemotherapy with capecitabine was started and she recovered from hydronephrosis 4 months after the start of treatment. After 32 months from the first treatment with capecitabine, the patient is presently alive without hydronephrosis due to continued chemotherapy.
AuthorsShinichi Yamauchi, Tsuyoshi Nakagawa, Mai Kasahara, Hitoshi Sugimoto, Toshiyuki Ishiba, Nobuko Tamura, Makoto Nagahara, Takanobu Sato, Kenichi Sugihara
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 12 Pg. 2077-9 (Nov 2012) ISSN: 0385-0684 [Print] Japan
PMID23267982 (Publication Type: Case Reports, English Abstract, Journal Article, Review)
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil
  • Adenocarcinoma, Scirrhous (drug therapy, secondary)
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Capecitabine
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Female
  • Fluorouracil (analogs & derivatives, therapeutic use)
  • Humans
  • Hydronephrosis (etiology)
  • Middle Aged
  • Peritoneal Neoplasms (drug therapy, secondary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: